Real-World Study on the Burden of Hidradenitis Suppurativa

NCT07323303 | Not Yet Recruiting

• 1 other identifier: PROxy85HS
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.

Conditions

Hidradenitis Suppurativa (HS)

Outcome Measures

Primary Outcomes (1)

• To estimate work productivity loss in patients with HS.

  Using the Work Productivity and Activity Impairment (WPAI) questionnaire. This questionnaire provides a quantitative measure of impairment over the last 7 days and includes four metrics: absenteeism (work time missed because of health issues during the past 7 days), presenteeism (impairment while working due to health issues during the past 7 days), overall work productivity loss (combination of absenteeism and presenteeism), and activity impairment.

  At recruitment

Secondary Outcomes (2)

• To estimate the QoL of patients with HS

  At recruitment

• To estimate pain intensity in patients with HS.

  At recruitment

Study Arms (1)

Patient with HS

Patient diagnosed with HS

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational Cohort OTHER

No specific intervention is assess in this study. Observational cohort.

Patient with HS

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with HS

You may qualify if:

• Patient diagnosed with HS;
• Aged ≥18 years;
• Able to read and understand French or English;
• Willing and able to provide written informed consent.

You may not qualify if:

• \. Participation in an interventional study for HS.

Sponsors & Collaborators

• PeriPharm: lead

MeSH Terms

Conditions

Hidradenitis Suppurativa

Condition Hierarchy (Ancestors)

Skin Diseases, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Suppuration; Skin Diseases; Skin and Connective Tissue Diseases; Hidradenitis; Sweat Gland Diseases

Central Study Contacts

Jean Lachaine, PhD

CONTACT

514-731-8207; jean.lachaine@peripharm.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 22, 2025
• First Posted: January 7, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: January 7, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share